| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-05 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.0001 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.22 | 0.0001 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.23 | 0.0002 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.2 | 0.0005 |